TD Cowen Reiterates Buy Rating on Eli Lilly (LLY)

TD Cowen analyst Steve Scala reiterated a Buy rating and $1,050.00 price target on Eli Lilly (NYSE: LLY).

The analyst commented, "A newer product portfolio with good growth prospects and late-stage agents near launch build confidence in LLY's above-average sales and EPS growth forecasts. Key franchises are subject to competition but best-in-class data for Mounjaro/Zepbound and productive R&D offer upside. Estimated 2023-30 EPS CAGR of 31% is well above the industry average, and dividend yield is attractive."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $887.16 yesterday.

You May Also Be Interested In

• Ashland said to explore sale amid takeover interest - Bloomberg
• Ashland (ASH) Declares $0.42 Quarterly Dividend; 2.2% Yield
• Hawaiian Electric Industries (HE) Misses Q2 EPS by 6c